Fosrolapitant/palonosetron

Small molecule

Also known as HR20013

Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.

—no market stage

Evidence outlook

Studies registered, no market-specific stage

Studies of this drug are registered, but none is matched to a market this site covers, so no stage is set and there is nothing to grade. The registry list shows each study.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Other / comorbidity
NCT06554184 · Fujian Shengdi Pharmaceutical Co., Ltd.
2024-09-03 – 2025-10-03 · Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents
What this study did
NCT05509634 · Fujian Shengdi Pharmaceutical Co., Ltd.
2022-09-21 – 2023-08-30 · Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy
What this study did
Phase 1 (1)
Other / comorbidity
NCT05465681 · Fujian Shengdi Pharmaceutical Co., Ltd.
2022-08-30 – 2023-01-13 · Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy
What this study did

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

No upcoming readouts on record for this asset.